Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes
- PMID: 20117261
- DOI: 10.1016/j.vaccine.2010.01.037
Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes
Abstract
We sought to determine susceptibility to highly pathogenic avian influenza (HPAI) H5N1 virus and to explore immune protection of inactivated H5N1 vaccine in streptozotocin-induced type 1 diabetic mice. Susceptibility of diabetic mice to an H5N1 virus was evaluated by comparing the median lethal dose (LD(50)) and the lung virus titers with those of the healthy after the viral infection. To evaluate the influence of diabetes on vaccination, diabetic and healthy mice were immunized once with an inactivated H5N1 vaccine and then challenged with a lethal dose of H5N1 virus. The antibody responses, survival rates, lung virus titers and body weight changes were tested. Mice with type 1 diabetes had higher lung virus titers and lower survival rates than healthy mice after H5N1 virus infection. Inactivated H5N1 vaccine induced protective antibody in diabetic mice, but the antibody responses were postponed and weakened. In spite of this, diabetic mice could be protected against the lethal virus challenge by a single dose of immunization when the amount of the antigen increased. These results indicated that type 1 diabetic mice were more susceptible to H5N1 influenza virus infection than healthy mice, and can be effectively protected by inactivated H5N1 vaccine with increased antigen.
Copyright 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.Arch Virol. 2011 Mar;156(3):387-95. doi: 10.1007/s00705-010-0860-4. Epub 2010 Nov 26. Arch Virol. 2011. PMID: 21110049
-
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10. Virology. 2008. PMID: 18786689
-
Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.Arch Virol. 2010 Apr;155(4):535-44. doi: 10.1007/s00705-010-0621-4. Epub 2010 Feb 27. Arch Virol. 2010. PMID: 20195654
-
Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.Vaccine. 2007 May 4;25(18):3554-60. doi: 10.1016/j.vaccine.2007.01.083. Epub 2007 Jan 30. Vaccine. 2007. PMID: 17293015
-
Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10. Vaccine. 2011. PMID: 21911027
Cited by
-
Influenza in High-Risk Hosts-Lessons Learned from Animal Models.Cold Spring Harb Perspect Med. 2020 Dec 1;10(12):a038604. doi: 10.1101/cshperspect.a038604. Cold Spring Harb Perspect Med. 2020. PMID: 31871227 Free PMC article. Review.
-
Influenza Virus and Glycemic Variability in Diabetes: A Killer Combination?Front Microbiol. 2017 May 22;8:861. doi: 10.3389/fmicb.2017.00861. eCollection 2017. Front Microbiol. 2017. PMID: 28588558 Free PMC article.
-
Respiratory Tract Infections in Diabetes - Lessons From Tuberculosis and Influenza to Guide Understanding of COVID-19 Severity.Front Endocrinol (Lausanne). 2022 Jul 26;13:919223. doi: 10.3389/fendo.2022.919223. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35957811 Free PMC article. Review.
-
Pathology of Equine Influenza virus (H3N8) in Murine Model.PLoS One. 2015 Nov 20;10(11):e0143094. doi: 10.1371/journal.pone.0143094. eCollection 2015. PLoS One. 2015. PMID: 26587990 Free PMC article.
-
A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.Virol J. 2010 Aug 21;7:197. doi: 10.1186/1743-422X-7-197. Virol J. 2010. PMID: 20727202 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials